Compare BMM & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMM | EVO |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | Canada | Germany |
| Employees | 68 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.1M | 568.6M |
| IPO Year | N/A | 2007 |
| Metric | BMM | EVO |
|---|---|---|
| Price | $4.00 | $1.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.23 |
| AVG Volume (30 Days) | ★ 217.5K | 83.4K |
| Earning Date | 11-23-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $1.33 |
| 52 Week High | $8.63 | $4.19 |
| Indicator | BMM | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 45.54 |
| Support Level | $3.47 | $1.50 |
| Resistance Level | $6.68 | $1.97 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 13.39 | 60.73 |
Blue Moon Metals Inc is a Canadian exploration stage company focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The projects of the company include the Nussir copper-gold-silver property in Norway (the "Nussir Property"), the Blue Moon zinc-copper-gold-silver property in California, USA (the "Blue Moon Property"), the NSG copper-zinc-gold-silver property in Norway (the "NSG Property") the Springer tungsten-molybdenum project in the Nevada, USA (the "Springer Property") and the Apex germanium-gallium-copper project in Utah, USA (the "APEX Property").
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.